<DOC>
	<DOCNO>NCT01146483</DOCNO>
	<brief_summary>This single-center , randomize , 2-period , 2-sequence , cross-over study .</brief_summary>
	<brief_title>Drug-drug Interaction Study Healthy Male Volunteers Following Administration Pantoprazole Rosuvastatin</brief_title>
	<detailed_description>Background : Notions use describe drug disposition review role drug membrane transporter discover . In near past , simple biophysical principle - lipophilicity passive diffusion - use explain drug absorption , distribution elimination . Today , 367 gene know human , membrane transporter occupy much central role . Rational : Drug influx/efflux transporter express various organ variable activity presence increase ( influx ) decrease ( efflux ) intracellular concentration drug specific organ . Therefore , intersubject variability activity transporter due genetic polymorphism concomitant drug treatment explain intersubject variability drug action . Rosuvastatin HMG-CoA reductase inhibitor substrate OATPs BCRP . There much information transporter-mediated disposition rosuvastatin . Literature suggest rosuvastatin transporter substrate influx OATP1B1 , 1B3 2B1 well efflux BCRP . The efflux rosuvastatin BCRP would major importance hepatocytes . BCRP would responsible excretion 30 % unchanged drug bile . To confirm hypothesis identify patient risk toxicity rosuvastatin , want perform drug-drug interaction study inhibitor BCRP namely , pantoprazole . With approach , confirm rosuvastatin real substrate BCRP suggest literature . Methodology : To determine change induce administration pantoprazole pharmacokinetics rosuvastatin healthy volunteer 16 healthy volunteer administer single dose rosuvastatin without ( placebo ) pantoprazole . Urine plasma analysis perform LC-MSMS . Pharmacokinetics analysis perform . Plasma urine concentration rosuvastatin analyse use noncompartmental method . Pharmacokinetic parameter calculate study Cmax , Tmax , AUC0-72 , AUC0-∞ , Kel , T1/2β , CL/F , CLr , Ae .</detailed_description>
	<mesh_term>Pantoprazole</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Vital Signs , EKG Clinical Laboratory Values within normal range Body mass index ( BMI ) [ 2029kg/m2 ] Caucasian male Age [ 1855 ] Healthy physical exam Non exsmoker Presence history intolerance hypersensibility proton pump inhibitor HMGCoA reductase inhibitor . Significant illness . History cardiovascular , kidney , liver gastrointestinal disease . Presence cardiovascular , pulmonary , hematologic , neurologic , psychiatric , endocrine , immunologic dermatologic disease . consumption investigational product donation blood previous 28 day precede study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>